Design and rationale of the EBBINGHAUS trial: A phase 3, double‐blind, placebo‐controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid‐lowering therapy—A cognitive study of patients enrolled in the FOURIER trial
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Some observational studies raised concern that statins may cause memory impairment, leading to a US Food and Drug Administration warning. Similar questions were raised regarding proprotein convertase subtilisin/kexin‐type 9 inhibitors (PCSK9i) and neurocognitive function. No prospectively designed study has evaluated the relationship between long‐term PCSK9i use and cognition changes. Patients with prior cardiovascular disease treated with maximally tolerated statin enrolled in FOURIER (the randomized, double‐blind, placebo‐controlled cardiovascular outcome study of the PCSK9i evolocumab) could participate in this prospective assessment of cognitive function (EBBINGHAUS). Key additional exclusion criteria for EBBINGHAUS were dementia, cognitive impairment, or other significant mental or neurological disorder. Cognitive testing was performed using the Cambridge Neuropsychological Test Automated Battery, a tablet‐based tool assessing executive function, working memory, memory function, and psychomotor speed at baseline, weeks 24 and 48, every 48 weeks thereafter, and study end. The primary endpoint was spatial working memory strategy index of executive function (SWMSI). The primary hypothesis was that evolocumab would be noninferior to placebo in the mean change from baseline over time in SWMSI. Fifteen hundred cognitively normal patients completing the assessments provided approximately 97% power to demonstrate that the upper 95% confidence interval for the treatment difference in mean change from baseline in SWMSI over time is <20% of the SD of the mean change in the placebo group. An exploratory analysis will compare neurocognitive function in patients with post‐baseline low‐density lipoprotein cholesterol <25 mg/dL. EBBINGHAUS will evaluate whether the addition of evolocumab to statin therapy affects cognitive function over time in patients with stable cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationNew Effect Size Rules of Thumb
Sawilowsky, S. S. (2009) · Journal of Modern Applied Statistical Methods · doi:10.22237/jmasm/1257035100 · Cited by 3,254
Statistical methods in psychology journals: Guidelines and explanations.
Wilkinson, L., & Task Force on Statistical Inference (1999) · American Psychologist · doi:10.1037/0003-066x.54.8.594 · Cited by 2,791
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Self-citationEfficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Self-citationSilverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483
Self-citationNicholls, S. J., Puri, R., Anderson, T., Ballantyne, C. M., Cho, L., Kastelein, J. J. P., Koenig, W., Somaratne, R., Kassahun, H., Yang, J., et al. (2016) · JAMA · doi:10.1001/jama.2016.16951 · Cited by 1,178
Self-citationSolomon, A., Kivipelto, M., Wolozin, B., Zhou, J., & Whitmer, R. A. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000231980 · Cited by 557
Central nervous system: cholesterol turnover, brain development and neurodegeneration
Dietschy, J. M. (2009) · bchm · doi:10.1515/bc.2009.035 · Cited by 394
Pravastatin and cognitive function in the elderly. Results of the PROSPER study
Trompet, S., Vliet, P., Craen, A. J. M., Jolles, J., Buckley, B. M., Murphy, M. B., Ford, I., Macfarlane, P. W., Sattar, N., Packard, C. J., et al. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5271-7 · Cited by 291
Lipinski, M. J., Benedetto, U., Escarcega, R. O., Biondi-Zoccai, G., Lhermusier, T., Baker, N. C., Torguson, R., Brewer, H. B., & Waksman, R. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv563 · Cited by 256
Statins and Cognitive Function: A Systematic Review
Richardson, K., Schoen, M., French, B., Umscheid, C. A., Mitchell, M. D., Arnold, S. E., Heidenreich, P. A., Rader, D. J., & deGoma, E. M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00007 · Cited by 250
Smith, P. J., Need, A. C., Cirulli, E. T., Chiba-Falek, O., & Attix, D. K. (2013) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2013.771618 · Cited by 176
Sabatine, M. S., Giugliano, R. P., Keech, A., Honarpour, N., Wang, H., Liu, T., Wasserman, S. M., Scott, R., Sever, P. S., & Pedersen, T. R. (2016) · American Heart Journal · doi:10.1016/j.ahj.2015.11.015 · Cited by 176
Self-citationBrain cholesterol metabolism and neurologic disease
Benarroch, E. E. (2008) · Neurology · doi:10.1212/01.wnl.0000333215.93440.36 · Cited by 68
Postmus, I., Trompet, S., de Craen, A. J. M., Buckley, B. M., Ford, I., Stott, D. J., Sattar, N., Slagboom, P. E., Westendorp, R. G. J., & Jukema, J. W. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m033969 · Cited by 67
Reynolds, C. A., Hong, M.-G., Eriksson, U. K., Blennow, K., Wiklund, F., Johansson, B., Malmberg, B., Berg, S., Alexeyenko, A., Grönberg, H., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq079 · Cited by 57
Shibata, N., Ohnuma, T., Higashi, S., Higashi, M., Usui, C., Ohkubo, T., Watanabe, T., Kawashima, R., Kitajima, A., Ueki, A., et al. (2005) · Psychiatric Genetics · doi:10.1097/00041444-200512000-00004 · Cited by 28
Cited by
Giugliano, R. P., Pedersen, T. R., Park, J.-G., De Ferrari, G. M., Gaciong, Z. A., Ceska, R., Toth, K., Gouni-Berthold, I., Lopez-Miranda, J., Schiele, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32290-0 · Cited by 682
Self-citationLloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Covington, A. M., DePalma, S. M., Minissian, M. B., Orringer, C. E., Smith, S. C., Waring, A. A., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.07.006 · Cited by 569
Cognitive function in a randomized trial of evolocumab
Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701131 · Cited by 492
Self-citationLloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., DePalma, S. M., Minissian, M. B., Orringer, C. E., & Smith, S. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.745 · Cited by 377
PCSK9 inhibitors: clinical evidence and implementation
Sabatine, M. S. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0107-8 · Cited by 338
Self-citation
Metadata
- Authors
- Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., Sabatine, M. S., Sever, P. S., Honarpour, N., Wasserman, S. M., Ott, B. R., & on behalf of the EBBINGHAUS Investigators
- Venue
- Clinical Cardiology
- Publisher
- Wiley
- Published
- 2017-02
- Volume
- 40
- Issue
- 2
- Pages
- 59-65
- ISSN
- 0160-9289 (ISSN-L)
- 1932-8737
- OpenAlex
- W2588492988
- Cited by
- 64
- References
- 19
- FWCI
- 11.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.